Sivia Capital Partners LLC Has $482,000 Position in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Sivia Capital Partners LLC boosted its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 394.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 30,498 shares of the company’s stock after purchasing an additional 24,336 shares during the quarter. Sivia Capital Partners LLC’s holdings in Dr. Reddy’s Laboratories were worth $482,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. Farther Finance Advisors LLC grew its stake in Dr. Reddy’s Laboratories by 43.2% in the 3rd quarter. Farther Finance Advisors LLC now owns 454 shares of the company’s stock valued at $36,000 after buying an additional 137 shares during the last quarter. Venturi Wealth Management LLC acquired a new stake in shares of Dr. Reddy’s Laboratories in the third quarter valued at about $60,000. Van ECK Associates Corp increased its stake in shares of Dr. Reddy’s Laboratories by 64.3% in the third quarter. Van ECK Associates Corp now owns 823 shares of the company’s stock worth $64,000 after purchasing an additional 322 shares during the period. GAMMA Investing LLC lifted its position in shares of Dr. Reddy’s Laboratories by 83.2% during the 3rd quarter. GAMMA Investing LLC now owns 1,447 shares of the company’s stock worth $115,000 after purchasing an additional 657 shares during the last quarter. Finally, Glenmede Trust Co. NA bought a new stake in Dr. Reddy’s Laboratories during the 3rd quarter valued at approximately $207,000. Institutional investors own 3.85% of the company’s stock.

Wall Street Analysts Forecast Growth

RDY has been the subject of a number of research analyst reports. Barclays cut their price target on Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th. StockNews.com cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th. Finally, Nomura downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th.

Dr. Reddy’s Laboratories Stock Performance

Shares of RDY stock traded down $0.11 during mid-day trading on Monday, reaching $15.31. The stock had a trading volume of 1,039,240 shares, compared to its average volume of 1,953,938. Dr. Reddy’s Laboratories Limited has a one year low of $13.43 and a one year high of $16.89. The firm has a market cap of $12.78 billion, a PE ratio of 24.46 and a beta of 0.53. The firm’s 50 day simple moving average is $14.84 and its 200 day simple moving average is $15.55. The company has a quick ratio of 1.36, a current ratio of 1.92 and a debt-to-equity ratio of 0.02.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.